What A1C measures, and what it misses
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
A1C is the single number most diabetes decisions are built on. It is useful, standardised and cheap, and it also hides a great deal.
Understanding both halves of that sentence is the difference between chasing a number and managing a condition.
Related pages: Type 2 diabetes
The bottom line
- A1C reflects average glucose over roughly the previous two to three months.
- Lowering A1C reduces small-vessel complications in the eyes, kidneys and nerves.
- A1C targets are individualised, and a lower number is not always better.
- A1C cannot show variability, low blood sugar or the pattern through the day.
- Time in range from continuous monitoring provides information A1C cannot.
- The best A1C target for older adults and those with heart disease.
- How much glucose variability matters independently of average.
- Whether time-in-range targets predict complications as well as A1C does.
The story, step by step
What the evidence labels mean
What the test measures
What happens
Sugar stuck to haemoglobin.
What the research shows
- Glucose in the blood attaches slowly and irreversibly to haemoglobin inside red cells. The higher the glucose, the more attaches.
- Red cells live about three months, so the proportion of glycated haemoglobin reflects average glucose over that period.
- The most recent month contributes roughly half the result, so recent changes show up faster than people expect.
- The result is reported as a percentage, or in mmol/mol in many countries. 6.5 percent equals 48 mmol/mol.
- Assays are standardised internationally, which is why the same thresholds are used everywhere.
- No fasting is required and the sample can be taken at any time of day.
Why it matters
The two-to-three-month window is why A1C is rechecked quarterly at most, and why a change in treatment cannot be judged after a fortnight.
What's still uncertain
- How much the weighting toward recent weeks varies between individuals.
- Differences in red cell lifespan between people and what they do to the result.
Read more
- NIDDK: The A1C test and diabetesGovernment
- MedlinePlus: Blood glucoseGovernment
Next: The translation
A1C as an average glucose
What happens
Rough conversions that help.
What the research shows
- An A1C of 6 percent corresponds to an estimated average glucose of about 126 mg/dL.
- 7 percent is about 154 mg/dL, 8 percent about 183, 9 percent about 212, and 10 percent about 240.
- Each 1 percent change in A1C corresponds to roughly 29 mg/dL in average glucose.
- These are population averages. For an individual, the true average can differ from the estimate by a meaningful margin.
- The relationship between A1C and average glucose varies between people, a difference sometimes called the glycation gap.
- This is one reason a person's meter readings can look consistently better or worse than their A1C suggests.
Why it matters
The conversion makes A1C concrete, which helps people connect a laboratory percentage to what they see on a meter.
What's still uncertain
- How large the individual glycation gap is and whether it should be measured.
- Whether estimated average glucose should replace the percentage entirely.
Read more
- NIDDK: The A1C test and diabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit
- MedlinePlus: Blood glucoseGovernment
Next: The target
Why it is not the same for everyone
What happens
Lower is better, up to a point, and not for everyone.
What the research shows
- An A1C below 7 percent is a common target for many non-pregnant adults, and reduces eye, kidney and nerve complications.
- A tighter target, closer to 6.5, may suit people early in the disease, without heart disease, on medicines that do not cause low blood sugar, and with a long life expectancy.
- A looser target, 8 percent or above, is appropriate for older adults, those with limited life expectancy, advanced complications, or a history of severe hypoglycemia.
- Large trials of very intensive glucose lowering in people with long-standing diabetes and heart disease did not show the expected benefit, and one found increased mortality.
- The harm in those trials is thought to relate to hypoglycemia and the aggressive combinations used, not to the lower glucose itself.
- Blood pressure and lipid control deliver larger cardiovascular benefit per unit of effort than pushing A1C down a further half point.
Why it matters
A target is a clinical decision about an individual, not a universal pass mark. Being told 7.4 is acceptable is often correct rather than a concession.
What's still uncertain
- The right targets for older adults with few complications.
- How to balance intensive control against hypoglycemia risk in practice.
Read more
- American Diabetes Association: standards of care resourcesNonprofit
- NIDDK: Managing diabetesGovernment
- NIDDK: Insulin, medicines and other diabetes treatmentsGovernment
Next: The blind spots
What A1C cannot show
What happens
An average conceals the pattern.
What the research shows
- A1C cannot distinguish steady glucose from wild swings. A person alternating between 50 and 250 can have the same A1C as someone steady at 150.
- It cannot show low blood sugar at all, so a dangerously hypoglycemic regimen can produce an admirable number.
- It cannot show when in the day problems occur, which is what actually guides a treatment change.
- It is distorted by anaemia, kidney disease, recent blood loss, pregnancy and some haemoglobin variants.
- It lags behind change, so it cannot guide a rapid adjustment.
- Glucose variability is associated with worse outcomes in some studies independent of average, though the evidence is not settled.
Why it matters
A good A1C is not by itself evidence of good control. The question that follows it should be how the days actually look.
What's still uncertain
- How much variability matters independently of average glucose.
- Whether reducing variability improves hard outcomes.
Read more
- NIDDK: The A1C test and diabetesGovernment
- CDC: Low blood sugar (hypoglycemia)Government
- American Diabetes Association: standards of care resourcesNonprofit
Next: Time in range
What continuous monitoring adds
What happens
The percentage of the day spent where you want to be.
What the research shows
- Continuous glucose monitors sample glucose in the fluid under the skin every few minutes and build a 24-hour picture.
- Time in range is the proportion of readings between 70 and 180 mg/dL. A common target for adults is above 70 percent.
- Time below range, under 70 mg/dL, is usually targeted at under 4 percent, with under 1 percent below 54.
- Roughly, a 10 percent increase in time in range corresponds to about a 0.5 percent fall in A1C.
- These metrics reveal overnight lows and post-meal spikes that A1C and occasional finger-stick checks both miss.
- Monitors are now used by many people with type 2 diabetes, including some not on insulin, though coverage and cost vary considerably.
Why it matters
Time in range answers the question A1C cannot: not how high on average, but how much of the day was spent where it should be.
What's still uncertain
- Whether time-in-range targets predict long-term complications as well as A1C.
- Who among people not using insulin benefits enough to justify the cost.
Read more
- MedlinePlus: Blood glucoseGovernment
- NIDDK: Managing diabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit